CEL-SCI Corp. is a biopharmaceutical company dedicated to improving the treatment of cancer and other infectious diseases by unleashing the power of the body’s immune system. The company’s flagship product is Multikine, the first immunotherapeutic agent being developed as a standard of care treatment for cancer.

The company’s Multikine has been designated as an orphan drug by the US Food and Drug Administration (FDA) and has recently begun a global Phase III trial in advanced primary head and neck cancer patients. In earlier trials, the drug was shown to kill approximately 50 percent of tumor cells before standard treatments start. Multikine also renders residual cancer cells that survive treatment more susceptible to radiation and chemotherapy.

Multikine has several novel characteristics that will differentiate it from the present generation of cancer vaccines: 1) The drug can be used off-the-shelf, making large-scale manufacturing possible; 2) It offers both active and passive immunity, indicating that no outside antigen is needed; 3) The drug is administered to cancer patients when the immune system is strongest (before surgery, radiation or chemotherapy), which CEL-SCI has found to be the optimal time.

It is believed that Multikine may have the potential to be a billion-dollar blockbuster drug, but the company also has other drugs in the pipeline. CEL-SCI’s other products are currently in various stages of pre-clinical development. CEL-2000 has shown promise as a therapeutic vaccine for rheumatoid arthritis. Initial tests in animals have shown that it may be more effective than Enbrel. CEL-1000, on the other hand, may be particularly suitable for development as a bio-defense agent.

Let us hear your thoughts below: